This article was originally published in The Tan Sheet
Executive SummaryRobert Ruffolo, Wyeth's president of research and senior VP, will retire later this year and will be succeeded by Mikael Dohlsten. Ruffolo joined Wyeth in 2000 and was responsible for all pharmaceutical research and development for the firm, including discovery, drug safety and metabolism, chemical and pharmaceutical development, clinical research and development and research operations. Wyeth President and CEO Bernard Poussot says Ruffolo helped "position our company for future growth through robust research and development programs in oncology, women's health, vaccines, inflammation, cardiovascular and metabolic diseases and neuroscience." Dohlsten was previously executive VP within pharmaceutical research and development/medicine at Boehringer Ingelheim...
You may also be interested in...
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.